U.S. Markets close in 2 hrs 14 mins

Sanofi Pasteur's new influenza vaccine accepted for review for European approval

Sanofi Pasteur, the vaccines division of Sanofi, announced that a decentralized marketing authorization application has been accepted for review in the European Union countries for a quadrivalent, or four-strain, formulation of Vaxigrip Sanofi Pasteur’s seasonal inactivated split-virion influenza vaccine produced at its facility in Val de Reuil, France. The file has been accepted for review by France’s Agence nationale de sécurité du medicament et des produits de santé, or ANSM, as the regulatory agency for the “Reference Member State”, and by national regulatory agencies from the EU countries.